Reproductive performance in dairy cows following postpartum treatment with gonadotrophin releasing hormone and/or prostaglandin: a field trial.
Three hundred and five Holstein Friesian cows were given either 250 micrograms gonadotrophin releasing hormone (GnRH) or saline on day 15 postpartum followed by 500 micrograms cloprostenol or saline on day 24 postpartum. Four treatment groups were formed using random allocation: Group I -- placebo (Day 15)/placebo (Day 24), Group II -- GnRH (Day 15)/placebo (Day 24), Group III -- placebo (Day 15)/cloprostenol (Day 24), Group IV -- GnRH (Day 15)/cloprostenol (Day 24). Double blind techniques were used during the follow-up period. Rectal palpation, to assess uterine involution and ovarian activity was performed just prior to each treatment and again at 28 days postpartum. In addition blood samples were collected at 15, 24 and 28 days postpartum for measurement of plasma progesterone. There were no significant differences among treatment groups with respect to services per conception, number of heats detected before first service and culling for infertility. Cows treated only with GnRH had an increased calving to first estrus and calving to first breeding interval, and tended to have an increased calving to conception interval. Treatment with cloprostenol significantly decreased calving to conception and calving to first observed estrus intervals. Treatment with GnRH on day 15 postpartum resulted in a significant increase in the subsequent incidence of pyometra and prebreeding anestrus. On the other hand, cloprostenol treatment on day 24 postpartum resulted in a decreased incidence of pyometra, regardless of GnRH treatment and a decreased incidence of prebreeding anestrus in GnRH treated cows compared to cows receiving only GnRH at day 15 postpartum.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D002417:Cattle / Q000502:physiology*; D002418:Cattle Diseases / Q000139:chemically induced / Q000188:drug therapy; D003008:Cloprostenol / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical / Q000662:veterinary; D004971:Estrus / Q000187:drug effects; D005260:Female; D010906:Pituitary Hormone-Releasing Hormones / Q000009:adverse effects / Q000494:pharmacology*; D010919:Placebos; D049590:Postpartum Period / Q000187:drug effects*; D011247:Pregnancy; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D012098:Reproduction / Q000187:drug effects*; D013492:Suppuration / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary; D013997:Time Factors; D014591:Uterine Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary
D010906:Pituitary Hormone-Releasing Hormones; D010919:Placebos; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol